AKT1 and pneumonitis: A second problem comprises the clinical adverse effects associated with PI3K/AKT/mTOR inhibition that include hyperglycemia, hyperlipidemia, bone marrow suppression, pneumonitis, stomatitis, and hepatotoxicity [184].